ReviewDer Pathologe2019
[Microsatellite instability : Review of methods and applications].
Review in Der Pathologe, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- [Secondary malignant neoplasms with underlying Lynch syndrome and coincidental ulcerative colitis].Chirurgie (Heidelberg, Germany) · 2025Article
- Article
- Diffusion kurtosis imaging with multiple quantitative parameters for predicting microsatellite instability status of endometrial carcinoma.Abdominal radiology (New York) · 2023Article
- Testing for deficient mismatch repair and microsatellite instability : A focused update.Pathologie (Heidelberg, Germany) · 2023Review
- [Molecular pathology of colorectal cancer].Pathologie (Heidelberg, Germany) · 2023Review
- [Testing deficient mismatch repair and microsatellite instability : A focused update. German version].Pathologie (Heidelberg, Germany) · 2023Review
- COLGALT1 is a potential biomarker for predicting prognosis and immune responses for kidney renal clear cell carcinoma and its mechanisms of ceRNA networks.European journal of medical research · 2022Article
- MSI testing : What's new? What should be considered?Der Pathologe · 2021Review
- [MSI testing : What is new? What should be considered? German version].Der Pathologe · 2021Review
- [Predictive diagnostics for checkpoint inhibitors].Der Pathologe · 2021Review
- Emerging role of SWI/SNF complex deficiency as a target of immune checkpoint blockade in human cancers.Oncogenesis · 2021Review
- Occurrence of High Microsatellite-Instability/Mismatch Repair Deficiency in Nearly 2,000 Human Adenocarcinomas of the Gastrointestinal Tract, Pancreas, and Bile Ducts: A Study From a Large German Comprehensive Cancer Center.Frontiers in oncology · 2021Article
- [Use of monoclonal antibodies in pathological diagnostics].Der Internist · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After introduction of the Bethesda microsatellite test panel demonstration of microsatellite instability (MSI) and/or loss of mismatch repair proteins (MMRD) was primarily used as a marker for cancer predisposition of Lynch syndrome (LS, previous: HNPCC). Nowadays MSI/MMRD has become an important biomarker to predict therapy response to checkpoint immunotherapies. MSI can be determined either by polymerase chain reaction (PCR)-based technologies with or without specification of fragment sizes or next generation sequencing (NGS) methods. Depending on the individual tumor entities, these test methods are used differently. Currently, MSI/MMRD is a tumor biomarker which covers a broad spectrum of indications in tumor pathology, especially in colorectal, endometrial and gastric cancer. In advanced carcinomas, MSI is an established predictor of therapy response to checkpoint-directed immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.